WallStSmart

Johnson & Johnson (JNJ)vsRapid Micro Biosystems Inc (RPID)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 284710% more annual revenue ($97.93B vs $34.38M). JNJ leads profitability with a 21.5% profit margin vs -145.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 4.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

RPID

Avoid

25

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -10.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$615.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
28.6%8/10

Strong operational efficiency at 28.6%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

RPID0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
29.1x4/10

Moderate valuation

PEG RatioValuation
4.142/10

Expensive relative to growth rate

EPS GrowthGrowth
-1.0%2/10

Earnings declined 1.0%

RPID4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$104.13M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.163/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.

Bull Case : RPID

Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : RPID

The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

JNJ profiles as a mature stock while RPID is a turnaround play — different risk/reward profiles.

RPID carries more volatility with a beta of 1.47 — expect wider price swings.

RPID is growing revenue faster at 11.1% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (57/100 vs 25/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Rapid Micro Biosystems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology firm at the forefront of revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, addressing the stringent regulatory requirements within these sectors. As the demand for rapid quality assurance solutions continues to grow, Rapid Micro is well-positioned to spearhead advancements in testing methodologies, ensuring product safety and integrity in highly regulated environments.

Visit Website →

Want to dig deeper into these stocks?